Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 9/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19173933 | 1.00 | HSD11B1 (0.56) | HSD11B1ALDH1A1SLC6A2SLC6A4SMN1; SMN2 | |
| SCHEMBL29318623 | 0.83 | LMNA (0.44) | HSD11B1ALDH1A1SMN1; SMN2LMNAKMT2A | |
| SCHEMBL23488970 | 0.82 | KDM1A (0.41) | HSD11B1ALDH1A1LMNA | |
| SCHEMBL20672639 | 0.82 | KDM1A (0.41) | HSD11B1ALDH1A1LMNA | |
| SCHEMBL20672423 | 0.82 | KDM1A (0.41) | HSD11B1ALDH1A1LMNA | |
| SCHEMBL23489055 | 0.82 | KDM1A (0.41) | HSD11B1ALDH1A1LMNA | |
| SCHEMBL24138672 | 0.82 | SMYD3 (0.39) | HSD11B1ALDH1A1LMNAKMT2AMEN1 | |
| SCHEMBL23489054 | 0.82 | KDM1A (0.41) | HSD11B1ALDH1A1LMNA | |
| SCHEMBL23489327 | 0.82 | KDM1A (0.41) | HSD11B1ALDH1A1LMNA | |
| SCHEMBL24273928 | 0.82 | KDM1A (0.41) | HSD11B1ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240238265-A1 | ADAMANTANE AMIDES AND THIOAMIDES FOR THE TREATMENT OF EBOLAVIRUS INFECTION | ARISAN THERAPEUTICS INC. (US) | 2024-07-18 | — | — | US | disclosed |
| US-20240238265-A1 | ADAMANTANE AMIDES AND THIOAMIDES FOR THE TREATMENT OF EBOLAVIRUS INFECTION | ARISAN THERAPEUTICS INC. (US) | 2024-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240238265-A1 | ADAMANTANE AMIDES AND THIOAMIDES FOR THE TREATMENT OF EBOLAVIRUS INFECTION | IFNAR1, NR4A3, NR0B2 | HSD11B1 2165/4885ALDH1A1 2758/4885SLC6A2 809/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.